New Brain Lesions at MR Imaging after Carotid Angioplasty and Stent Placement

Radiology ◽  
2002 ◽  
Vol 224 (2) ◽  
pp. 361-365 ◽  
Author(s):  
Hans P. M. van Heesewijk ◽  
Jan Albert Vos ◽  
Elisabeth S. Louwerse ◽  
Jos C. van den Berg ◽  
Timotheus T. C. Overtoom ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Stent Placement ◽  
Brain Lesions ◽  
Carotid Angioplasty

scholarly journals Age differential between outcomes of carotid angioplasty and stent placement and carotid endarterectomy in general practice

2012 ◽  
Vol 55 (1) ◽  
pp. 72-78 ◽  
Author(s):  
Rakesh Khatri ◽  
Saqib A. Chaudhry ◽  
Gabriela Vazquez ◽  
Gustavo J. Rodriguez ◽  
Ameer E. Hassan ◽  
...  
Keyword(s):  
General Practice ◽  
Carotid Endarterectomy ◽  
Stent Placement ◽  
Carotid Angioplasty

scholarly journals Carotid Angioplasty and Stent Placement after EVA-3S Trial

Stroke ◽  
2007 ◽  
Vol 38 (6) ◽  
pp. 1993-1996 ◽  
Author(s):  
Adnan I. Qureshi
Keyword(s):  
Stent Placement ◽  
Carotid Angioplasty

Proton MR Spectroscopy and MR Imaging in Acute and Chronic Multiple Sclerosis — Ringlike Appearances in Acute Plaques

1996 ◽  
Vol 37 (1P1) ◽  
pp. 278-287 ◽  
Author(s):  
A.-M. Landtblom ◽  
L. Sjöqvist ◽  
B. Söderfeldt ◽  
H. Nyland ◽  
K.-Å. Thuomas
Keyword(s):  
Multiple Sclerosis ◽  
Relaxation Time ◽  
Mr Imaging ◽  
Brain Lesions ◽  
T2 Relaxation Time ◽  
Healthy Individuals ◽  
T2 Relaxation ◽  
Proton Mrs ◽  
Proton Mr Spectroscopy ◽  
The Core

Purpose: We wanted to compare the metabolite status of brain lesions in different clinical subtypes of multiple sclerosis (MS). Two acute MS lesions with ringlike appearances were also investigated. Material and Methods: Twenty-three clinically stable MS patients, 2 patients with acute relapses, and 15 healthy individuals were examined by MR imaging and localized proton MRS. Results: No metabolite differences were seen in plaques of different subtypes. Decreased NAA/Cr and NAA/choline ratios as well as increased inositol/Cr ratios were observed in the plaques of the clinically stable or chronic active MS patients as compared with controls. The ring plaques had hyperintense cores with surrounding halos, separated from the cores by rings with low signal intensity in T2-weighted images. The core exhibited a prolonged T2 relaxation time. Proton spectra initially contained lactate. Conclusion: No differences between the metabolite status of nonacute plaques in different clinical subtypes could be detected. The ring plaques contained lactate signals indicating oedema, inflammation, and macrophage invasion, and may be transition forms between acute oedematous lesions and chronic demyelinated plaques.

Reduced artefacts and improved assessment of hyperintense brain lesions with BLADE MR imaging in patients with neurofibromatosis type 1

2009 ◽  
Vol 39 (11) ◽  
pp. 1216-1222 ◽  
Author(s):  
Thekla von Kalle ◽  
Bernd Blank ◽  
Claudia Fabig-Moritz ◽  
Peter Müller-Abt ◽  
Michael Zieger ◽  
...  
Keyword(s):  
Mr Imaging ◽  
Neurofibromatosis Type 1 ◽  
Neurofibromatosis Type ◽  
Brain Lesions

Open-label Phase I Clinical Study to Assess the Safety of Intravenous Eptifibatide in Patients Undergoing Internal Carotid Artery Angioplasty and Stent Placement

Neurosurgery ◽  
2001 ◽  
Vol 48 (5) ◽  
pp. 998-1005 ◽  
Author(s):  
Adnan I. Qureshi ◽  
Zulfiqar Ali ◽  
M. Fareed K. Suri ◽  
Stanley H. Kim ◽  
Richard D. Fessler ◽  
...  
Keyword(s):  
Phase I ◽  
Stent Placement ◽  
Bleeding Complications ◽  
Study Patient ◽  
Carotid Angioplasty ◽  
Open Label ◽  
End Point ◽  
Open Label Phase ◽  
Ischemic Events ◽  
Neurointerventional Procedures

Abstract OBJECTIVE Eptifibatide, a competitive platelet glycoprotein IIb-IIIa receptor inhibitor with high selectivity and a short half-life, has been demonstrated to reduce the risk of ischemic events associated with coronary interventions. However, its role in neurointerventional procedures needs to be analyzed. We report the results of an open-label Phase I study to evaluate the safety of the use of eptifibatide during carotid angioplasty and stent placement. METHODS Each study patient received eptifibatide administered intravenously as a 135-μg/kg single-dose bolus, then a 0.5-μg/kg/min infusion for 20 to 24 hours during carotid angioplasty and stent placement. The primary efficacy end point was the 30-day composite occurrence of death, cerebral infarction, transient ischemic attack, and unplanned or urgent surgical intervention, thrombolysis, or subsequent percutaneous revascularization. The primary safety end point was bleeding. Bleeding complications were classified as major (hemoglobin decrease >5 g/dl), minor (hemoglobin decrease 3–5 g/dl), or insignificant. RESULTS Ten patients (mean age, 73 yr; four men) were treated by use of the study protocol. One patient developed a minor stroke postprocedurally (National Institutes of Health Stroke Scale score of 21 at 24 h that improved to 1 at 7 d). Three patients underwent scheduled coronary artery bypass graft surgery 4 to 12 days after undergoing carotid angioplasty and stent placement. At 1-month follow-up, no new ischemic events were observed. Major or minor bleeding was not observed in any patient. Insignificant bleeding was observed in two patients. CONCLUSION The use of eptifibatide as an adjunct to carotid angioplasty and stent placement seems to be safe. Further studies are required to analyze the effectiveness and role of eptifibatide in neurointerventional procedures.

Sign in / Sign up

Export Citation Format

Share Document